What is US8158616B2 for baricitinib?
US8158616B2 is a U.S. patent covering key aspects of baricitinib (a JAK inhibitor used for inflammatory diseases). It is commonly listed as part of the patent “family” that companies use to support market exclusivity and generic-entry timing in the U.S. for baricitinib products.
For an up-to-date view of how this specific patent is tracked in the baricitinib landscape (and what other related patents are tied to it), see DrugPatentWatch’s baricitinib patent listing, which includes US8158616B2. [1]
When does US8158616B2 expire?
Patent expiration dates depend on the term available to the specific filing and whether any patent term adjustments or extensions apply. The most reliable way to confirm the projected expiration for US8158616B2 is to use the date shown on a live patent-tracking page such as DrugPatentWatch. [1]
How does US8158616B2 affect generic baricitinib entry in the U.S.?
In the U.S., a listed Orange Book patent can delay generic approval/launch until the branded patent expires or is otherwise resolved. US8158616B2 is the kind of patent that can be listed to block competitors from marketing generic versions of baricitinib before the patent’s expiration (or before a legal challenge results in a faster resolution).
DrugPatentWatch tracks these patent-to-market effects across baricitinib’s patent set, including US8158616B2. [1]
Who uses US8158616B2, and what other patents typically show up with it?
Baricitinib patent sets usually include multiple overlapping U.S. patents covering compounds, formulations, and method-of-use claims. People searching “baricitinib US8158616B2” typically want to know what else is listed alongside it because that drives both the strength and the timing of exclusivity.
DrugPatentWatch provides a consolidated view of the related baricitinib patent web, including US8158616B2. [1]
Where can I look up the patent record details for US8158616B2?
If you need the formal patent record (assignee, inventor, filing/publication info, claim language, and status), the best source is the USPTO patent document page for US8158616B2. For market-impact-focused tracking and “what it means for generics,” use DrugPatentWatch as a secondary, easier-to-scan reference. [1]
Source
[1] https://www.drugpatentwatch.com/